ScholarLens Back to search
2018•Journal of the Advanced Practitioner in OncologyOpen access

Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer

Tyler Beardslee, Justin Lawson

Open full text 28 citations

Abstract

mutation-positive NSCLC.

About this research paper

What this paper is about

mutation-positive NSCLC.

Why it matters

OpenAlex reports 28 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

mutation-positive NSCLC.

Key concepts: Alectinib, Crizotinib, Ceritinib, Medicine, Anaplastic lymphoma kinase, ALK inhibitor, Lung cancer, Oncology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer — Research Paper | ScholarLens